Position in AUPH
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$622,578
New position
Shares Held
36,687
first reported quarter
Ownership
0.028%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#123
of 279 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026ZACKS INVESTMENT MANAGEMENT holds $33,185,332 across 8 Biotechnology names. AUPH ranks #4 (1.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
55,052 | $27,345,979 | |
| 2 | HALO |
Halozyme Therapeutics, Inc.
|
32,627 | $2,553,715 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
8,417 | $2,533,769 | |
| 4 | AUPH |
Aurinia Pharmaceuticals Inc.
This page
|
36,687 | $622,578 | |
| 5 | LCTX |
Lineage Cell Therapeutics, Inc.
|
42,084 | $55,130 | |
| 6 | AGEN |
Agenus Inc
|
10,550 | $32,283 | |
| 7 | INO |
Inovio Pharmaceuticals, Inc.
|
26,435 | $29,078 | |
| 8 | GERN |
Geron Corp
|
10,000 | $12,800 |
All Filings in AUPH
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $622,578 | 36,687 | Shares | Sole | 2026-08-13 | |
| No filing history on record for this holder in this stock. | ||||||